TY  - JOUR
AU  - Alvarez-Larrán, Alberto
AU  - Pérez-Encinas, Manuel
AU  - Ferrer-Marín, Francisca
AU  - Hernández-Boluda, Juan Carlos
AU  - Ramírez, María José
AU  - Martínez-López, Joaquín
AU  - Magro, Elena
AU  - Cruz, Yasmina
AU  - Mata, María Isabel
AU  - Aragües, Pilar
AU  - Fox, María Laura
AU  - Cuevas, Beatriz
AU  - Montesdeoca, Sara
AU  - Hernández-Rivas, José Angel
AU  - García-Gutiérrez, Valentín
AU  - Gómez-Casares, María Teresa
AU  - Steegmann, Juan Luis
AU  - Durán, María Antonia
AU  - Gómez, Montse
AU  - Kerguelen, Ana
AU  - Bárez, Abelardo
AU  - García, Mari Carmen
AU  - Boqué, Concepción
AU  - Raya, José María
AU  - Martínez, Clara
AU  - Albors, Manuel
AU  - García, Francesc
AU  - Burgaleta, Carmen
AU  - Besses, Carlos
AU  - Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas
PY  - 2016
DO  - 10.3324/haematol.2016.152769
UR  - https://hdl.handle.net/10668/25112
T2  - Haematologica
AB  - Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved with hydroxyurea alone or with the combination of hydroxyurea plus phlebotomies. However,...
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Blood Cell Count
KW  - Combined Modality Therapy
KW  - Drug Resistance
KW  - Female
KW  - Hematocrit
KW  - Humans
KW  - Hydroxyurea
KW  - Male
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Phenotype
KW  - Phlebotomy
KW  - Polycythemia Vera
KW  - Registries
KW  - Risk
KW  - Spain
KW  - Thrombosis
KW  - Time Factors
KW  - Treatment Outcome
KW  - Young Adult
TI  - Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
TY  - research article
VL  - 102
ER  -